公开(公告)号：KR101147849B1

公开(公告)日：2012-05-24

申请号：KR1020110072875

申请日：2011-07-22

Applicant: 전남대학교산학협력단

Inventor： 이동원 ,  김상희 ,  박종성

IPC: G01N33/15 ,  C12Q1/02 ,  C12M1/34 ,  C12M1/42

Abstract: PURPOSE: A drug test apparatus applied in developing a novel drug is provided to quantitatively and qualitatively output drug screening data. CONSTITUTION: A drug test apparatus(100) comprises: a base part having a cell culture space for culturing cells; a cell stimulation unit(130) which is formed in a bimetal structure in the cell culture space of the base part and a heating unit for converting electricity into heat; a cell weight sensing unit(133) which has the cell stimulation unit and senses cell weight change; and an electricity resistance sensing unit(135) for sensing impedance change of cells. The apparatus further comprises a drug delivery unit(140). The drug delivery unit has piezoelectric polymers.

Abstract translation: 目的：提供一种应用于开发新药的药物测试仪器，用于定量和定性地输出药物筛选数据。 构成：药物测试装置（100）包括：具有用于培养细胞的细胞培养空间的基底部分; 形成在基部的细胞培养空间中的双金属结构的细胞刺激单元（130）和将热量转换成热量的加热单元; 具有细胞刺激单元并感测细胞重量变化的细胞重量感测单元（133）; 以及用于感测单元的阻抗变化的电阻感测单元（135）。 该装置还包括药物输送单元（140）。 药物输送单元具有压电聚合物。

公开(公告)号：KR1020150010326A

公开(公告)日：2015-01-28

申请号：KR1020130085180

申请日：2013-07-19

Applicant: 전남대학교산학협력단

Inventor： 강형식 ,  박민 ,  윤일주 ,  정윤화 ,  김상희 ,  강건욱 ,  임채민

IPC: A61K31/34 ,  A61K31/166 ,  A61K31/16 ,  A61P3/04

Abstract: The present invention relates to a composition for preventing or treating obesity and type 2 diabetes, or hepatic steatosis and, more specifically, to a composition for preventing or treating obesity and type 2 diabetes, or hepatic steatosis, containing derivatives including a main adipose differentiation promotion factor inhibitor or biaryl amide as an active ingredient. Additionally, by inhibiting a main adipose differentiation promotion factor and increasing Wnt10b, the composition according to the present invention can control differentiation of adipocytes, and increase insulin resistance and glucose resistance, thereby being effectively used for treating obesity and type 2 diabetes, or hepatic steatosis.

Abstract translation: 本发明涉及用于预防或治疗肥胖症和2型糖尿病或肝脂肪变性的组合物，更具体地，涉及用于预防或治疗肥胖症和2型糖尿病或肝脂肪变性的组合物，其包含主要脂肪分化促进的衍生物 因子抑制剂或联芳基酰胺作为活性成分。 另外，通过抑制主要的脂肪分化促进因子和增加Wnt10b，本发明的组合物可以控制脂肪细胞的分化，增加胰岛素抵抗和葡萄糖耐量，从而有效地用于治疗肥胖和2型糖尿病或肝脂肪变性 。